Platinum Sponsors
Astrazeneca
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
- www.astrazeneca.com
- Booth no. : 1
Daiichi Sankyo
With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.
- www.daiichisankyo.com
- Booth no. : 12
MSD
At MSD, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry.
- www.msd.com
- Booth no. : 17
Gold Sponsors
Gilead
Gilead is creating the future of oncology to help bring more life to people with cancer. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies and unexpected clinical combinations. From antibody-drug conjugates to small molecules our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers.
- www.gilead.co.uk
- Booth no. : 16
Eli Lilly and Company
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe.
- www.lilly.com
- Booth no. : 2
Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
- www.novartis.com
- Booth no. : 13
Pfizer Oncology
Pfizer Oncology is committed to advancing medicines wherever we believe we can make a difference for people living with cancer. We have an industry-leading portfolio of 24 approved cancer medicines & biosimilars across 30+ indications—and are focused on delivering breakthroughs in breast and genitourinary cancer, hematology and precision medicine.
- www.pfizer.com
- Booth no. : 18
Pierre Fabre
Pierre Fabre is a French health and beauty care company present in over 100 countries. Oncology is one of our main priorities focusing on targeted therapies, biotherapies and immuno-oncology. For 60 years, the better-being of individuals has been key to the development of our products. Our objective is to improve the treatment of patients with diseases presenting high medical needs.
- www.pierre-fabre.com
- Booth no. : 15
Roche
Roche is a pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, hematology and beyond.
Seagen
Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.
- www.seagen.com
- Booth no. : 14
Bronze Sponsors
Exact Science
Exact Sciences is a leading, global cancer diagnostics company. From early detection to diagnosis and treatment guidance, the company is offering and further developing a suite of tests to enable personalized care at all stages of the disease. In early breast cancer, the Oncotype DX test is the only test validated to identify patients likely to benefit from chemotherapy.
- www.exactsciences.com
- Booth no. : 24
Stemline, A Menarini Group Company
Stemline, A Menarini Group Company is committed to making a difference in cancer patients’ lives. We invest in developing precision medicine through our pipeline of investigational drugs. Partnering with cancer experts and research institutions globally, we aim to improve our understanding of cancer to enable personalized care from early detection to precision medicine.
- www.menarini.com
- Booth no. : 29
Exhibitors
Cerca Biotech GmbH
Cerca Biotech is a company specialising in women’s health, especially Oncology and Pregnancy. MammaTyper® is our first to market product, an RT-qPCR assay for the determination of biopsy biomarker content for ER, PR, HER2 and Ki-67. Talk to us about how we can help you quantitate Low HER2, Low ER and get a more reliable Ki-67 result; all of which will enable the Oncologist to better treat the patient with existing and new pharmaceuticals.
- www.cercabiotech.com
- Booth no. : 6
Greenwich LifeSciences
Greenwich LifeSciences has commenced Flamingo-01 Phase III clinical trial in the US and EU (planned), administering GLSI-100 in HER2/neu positive patients with residual disease or high-risk pCR who have completed neoadjuvant/adjuvant trastuzumab based treatment. In a previously completed Phase IIb clinical trial in the HER2/neu positive adjuvant setting, no breast cancer recurrences were observed after median 5 years of follow-up.
- www.greenwichlifesciences.com
- Booth no. : 30
Reveal Genomics
REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to develop innovative diagnostic tools to define the best therapeutic options for patients with cancer. It uses pioneering techniques, sophisticated computer applications, and machine learning to uncover new cancer research data and develop new biomarkers with clear clinical utility; spin-off company of Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, and Vall d'Hebrón Institute of Oncology (VHIO).
- www.reveal-genomics.com
- Booth no. : 8
Syantra Inc.
Syantra is a precision biotechnology company changing the way cancer is detected and treated. The company’s flagship product, Syantra DX™ Breast Cancer, is available today across Canada, is CE marked and coming soon to Europe, and will be available to US residents in the second half of 2023.
- www.syantra.com
- Booth no. : 26
Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions, including cancer. We are working with Immunicom in Europe to introduce the LW-02 Column for Immunopheresis® therapy, for adult patients with advanced, refractory triple negative breast cancer.
- www.terumobct.com
- Booth no. : 25
Veracyte, Inc.
Veracyte is a global diagnostics company that improves care throughout the patient journey. Our advanced diagnostic tests answer important clinical questions in eight of ten most prevalent cancers by incidence in the United States. Our solutions help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment.
- www.veracyte.com
- Booth no. : 4
Societies
ABC Global Alliance
The ABC Global Alliance, is a non-profit association in Portugal, is a multi-stakeholder platform for all those interested in collaborating on common projects related to advanced breast cancer (ABC). Our goal is to improve and extend the lives of women and men living with ABC in all countries worldwide and to fight for a cure.
- www.abcglobalalliance.org
- Booth no. : 28
GBG Forschungs GmbH
GBG Forschungs GmbH (GBG) represents a professional institute of breast cancer research and is dedicated to continuously improving the treatment of breast cancer patients for over 20 years. GBG is headed by Professor Sibylle Loibl, MD, CEO and, as the largest German academic breast cancer study group, can build on the scientific experience gained from over 60,000 patient data. The clinical study program focus on the investigation of advanced therapy options and new drugs in all stages of breast cancer.
- www.gbg.de
- Booth no. : 23